Navigation Links
New drug could reduce tissue damage after heart attack

A study led by UCL (University College London) scientists has designed a new drug that inhibits the adverse effects of C reactive protein (CRP), a protein that contributes to tissue damage in heart attacks and strokes. The findings, published in the journal Nature, suggest that targeting CRP may produce both immediate and long-term clinical benefits following a heart attack.

CRP is normally present at trace levels in the blood but its concentration increases sharply in almost all diseases including trauma, infection, strokes and chronic illnesses such as rheumatoid arthritis and Crohn's disease. CRP levels also rise dramatically after a heart attack. Patients with the greatest and most persistent increases in CRP concentration suffer higher mortality, and CRP is always deposited in and around the damaged heart tissue.

Inflammation contributes significantly to the extent of heart attack damage and this can be exacerbated by CRP. The UCL team has previously shown that human CRP increases the severity of damage in experimental models of heart attack and stroke. This first identified CRP as a valid therapeutic target. The present collaborative study has now rationally designed a potent small molecule inhibitor of CRP.

The new compound, bis(phosphocholine)-hexane, is bound by CRP, inhibits all CRP functions in the test tube, and blocks the tissue damaging effect of CRP in an experimental heart attack model.

Professor Mark Pepys, of the UCL Centre for Amyloidosis and Acute Phase Proteins, whose work on CRP has been supported by the Medical Research Council since 1979, says: "Although heart attacks are responsible for about one third of all deaths in developed countries, most patients survive a first heart attack. However, if they have a large scar, patients go on to develop heart failure which is eventually fatal. Reducing the immediate damage is thus critically important.

"We had previously invented a new mechanism of drug action for small molecules bound by target proteins. Coupled with knowledge of the structure and properties of CRP, we were able to design the CRP inhibitor.

"We now propose to develop a CRP inhibitor as rapidly as possible for testing in patients with heart attacks.

"The drug would be given as soon as patients arrived in hospital. If effective, it would reduce the amount of damage in the heart, thus limiting both early mortality and the size of the scar left in the heart.

"Provided adequate support is available, it should be possible to undertake clinical trials of CRP inhibition within a couple of years. If the treatment proves safe and effective, we also aim to investigate its effectiveness in strokes.

"It is likely that CRP contributes to tissue damage in a range of diseases in which CRP levels are greatly increased, and the inhibition of CRP may thus find broad application in medicine."

Patents, patent applications and proprietary knowledge related to this work are owned by Pentraxin Therapeutics Ltd, a UCL spin out company of which Professor Pepys is director.


'"/>

Source:University College London


Related biology news :

1. Protein discovery could unlock the secret to better TB treatment
2. Tiny particles could solve billion-dollar problem
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
5. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
6. How the environment could be damaging mens reproductive health
7. Dead zone area in Gulf could be increasing, researchers say
8. Growth in biomass could put US on road to energy independence
9. Nano-bumps could help repair clogged blood vessels
10. Researchers develop assay that could be applied to drug screening
11. Currents could disrupt ocean food chain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... Florida , February 16, 2017 ... with the infusion of innovative telemedicine application, new ... services that are experiencing a boom worldwide. The ... the advancement of technologies, services and new therapies ... (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/15/2017)... ... February 15, 2017 , ... Park Systems , ... a powerful AFM operating software that drastically boosts productivity with single click reliable nanoscale ... of the functions of setting up and taking the image once done manually by ...
(Date:2/15/2017)... Pa. , Feb. 15, 2017 Windtree ... company focused on developing aerosolized KL4 surfactant therapies for ... (including a slide presentation) at 8:00 AM EST on ... AEROSURF phase 2 clinical program, the recently announced closing ... and development activities. To participate in the ...
Breaking Biology Technology: